Dr. Mike Ryan, executive director of the World Health Organization health emergencies program, said it’s too early to comment on the remdesivir trial results released earlier today.
“It’s always very important that we consider all publications related to them, it can sometimes take a number of publications to determine of the ultimate impact of a drug is,” Ryan said.
“I think a lot more data will come out, we’re all hoping, and fervently hoping, that one or more of the treatments currently under observation and under trial will result in altering clinical outcomes and improving clinical outcomes,” he added.
Dr. Maria Van Kerkhove, the technical lead for the coronavirus response with WHO, explained the agency generally pulls together all the evidence from several studies, will review it and critique it.
Currently, WHO is conducting “living reviews” on about 30 topics right now, in peer-reviewed journals and publications.
“Typically, you don’t have one study that will come out that will be a game changer,” Van Kerkove said.
If one proves to be a game changer, WHO will adjust its guidance, Van Kerkhove said, “But there is a process for this to take place and we’re really grateful for all of the scientists and experts that work with us to, to help us develop this guidance and understand all of this research that’s coming out.”
What this is about: Pharmaceutical company Gilead Sciences said today it is “aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19.”
Source: http://rss.cnn.com/~r/rss/cnn_topstories/~3/ZPUOVhV5MwA/index.html
